Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo

Abstract Mesenchymal stem cells (MSCs) can promote tumor growth in a mouse xenograft model, but the exact mechanism remains unclear. In this study, we investigated the effects of bone marrow MSC-derived exosomes (MSC-exosomes) on tumor growth in vitro and in vivo . Our results showed that MSC-exosom...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2012-02, Vol.315 (1), p.28-37
Main Authors: Zhu, Wei, Huang, Ling, Li, Yahong, Zhang, Xu, Gu, Jianmei, Yan, Yongmin, Xu, Xiaomeng, Wang, Mei, Qian, Hui, Xu, Wenrong
Format: Article
Language:English
Subjects:
Animals
bone marrow
Bone Marrow Cells - cytology
Bone Marrow Cells - metabolism
Cell Differentiation - physiology
Cell Growth Processes - physiology
Exosome
exosomes
Exosomes - physiology
Hematology, Oncology and Palliative Medicine
Humans
Immunohistochemistry
Male
MAPK pathway
Mesenchymal stem cell
Mesenchymal Stromal Cells - cytology
Mice
Mice, Inbred BALB C
Neoplasms - pathology
stem cells
Tumor growth
vascular endothelial growth factors
Xenograft model
Xenograft Model Antitumor Assays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mesenchymal stem cells (MSCs) can promote tumor growth in a mouse xenograft model, but the exact mechanism remains unclear. In this study, we investigated the effects of bone marrow MSC-derived exosomes (MSC-exosomes) on tumor growth in vitro and in vivo . Our results showed that MSC-exosomes promoted tumor growth in vivo . MSC-exosomes enhanced vascular endothelial growth factor (VEGF) expression in tumor cells by activating extracellular signal-regulated kinase1/2 (ERK1/2) pathway. Inhibition of ERK1/2 activation reserved the increase of VEGF level by MSC-exosomes. Our findings demonstrate a new mechanism through which MSC-exosome-mediated cell–cell interactions may contribute to tumor progression.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2011.10.002